Cheapest Tirzepatide: The Real Rankings

The ranking: every tirzepatide option by price

Ranks 2–5 overlap in practice depending on program and dose; the sections below explain when compounded actually beats brand vials and when it does not.

Compounded at $199–$449: cheapest, with post-shortage caveats

Compounded tirzepatide is the price floor, but a floor with structure. Entry doses around 2.5–5 mg typically price near $199–$299 a month through telehealth programs, while higher maintenance doses climb toward $449. The regulatory backdrop tightened first for this molecule: the FDA declared the tirzepatide shortage resolved in December 2024, restricting mass 503A copies, so legitimate access now runs through personalized formulations prescribed via telehealth.

The vetting rules are the same as for semaglutide, a named licensed US pharmacy, a genuine prescriber evaluation, explicit titration, no "research use" framing, and the sub-$150 corner of the tirzepatide market deserves extra scrutiny because the ingredient is costlier than semaglutide. The compounded vs brand guide covers the framework differences in depth.

Watch the fee architecture as closely as the headline rate. Common patterns in the tirzepatide tier: membership fees billed separately from medication, "starting at" prices that apply only to 2.5 mg, escalation clauses that reprice at each dose step, and long prepaid packages sold before you know how you tolerate the drug. The defensible structure is monthly billing, an all-in price per dose level published up front, and the freedom to stop without penalty, since dose changes and molecule switches are normal events in this treatment, not exceptions.

LillyDirect vials: where brand undercuts expectations

Lilly selling Zepbound single-dose vials at $349–$499 reshaped this ranking. It is authentic, FDA-approved tirzepatide, purchased direct, at less than half of pen list price.

The dose structure decides its rank. The $349 tier covers only 2.5 mg, the dose standard titration uses for about four weeks, so the durable price is $499. That means: at entry doses, compounded ($199–$299) clearly undercuts brand ($349). At maintenance doses, compounded ($300–$449) and brand ($499) nearly converge, and the $50–$150 monthly gap buys the FDA-approved finished product, single-dose sterility, and Lilly's supply chain. Many cash payers reasonably start compounded and reassess at maintenance; the full dose grid is in the tirzepatide cost guide.

Factor in the format honestly as well: single-dose vials mean drawing your weekly dose with a needle and syringe. Most people manage it easily after the first week or two, but anyone unwilling to do so is really choosing between insured pens and compounded multi-dose vials, and the ranking above reshuffles accordingly.

The insurance route, including the sleep apnea angle

Where it exists, coverage beats every cash tier: $25–$50 a month for brand Zepbound pens. Tirzepatide has one coverage lever semaglutide lacks in kind: Zepbound is FDA-approved for obstructive sleep apnea, an indication that can unlock coverage, including some Medicare coverage, where weight loss alone is excluded. Patients with diagnosed OSA should raise this explicitly, because the prior authorization pathway is different and often stronger.

Mounjaro adds a second door for type 2 diabetics: diabetes coverage is far more routine, and a manufacturer savings card can reduce copays for commercially insured patients. Neither door helps a cash payer without those diagnoses, which is most of the market, but checking takes minutes and the payoff is thousands per year. Step-by-step formulary and prior auth tactics are in the GLP-1 insurance guide.

Sequence matters when you hold both a diagnosis and a budget: exhaust the indication-based coverage route first, because approval converts a $4,000–$6,000 annual cash spend into $300–$600, then fall back to the cash tiers only once a denial is final and appealed. Running both tracks in parallel, buying compounded while the prior authorization winds through review, is common and reasonable; just avoid prepaying long cash packages days before a coverage decision lands.

The verdict: true first-year cost per path

Ranking by realistic first-year totals, assuming standard titration from 2.5 mg:

• Insured with coverage: $300–$600. Unbeatable; always check first.
• Compounded throughout: roughly $2,400–$4,800 depending on program and final dose.
• LillyDirect throughout: about $5,700, one month at $349 plus eleven at $499, for the approved product end to end.
• Hybrid, compounded then brand vials at maintenance: lands between, and is increasingly common.
• Retail pens: $12,828–$13,032; the number exists to be avoided.

All routes require meeting the standard criteria, BMI 30-plus or 27 with a comorbidity, confirmed by a licensed provider; the assessment is the two-minute starting point. To price the telehealth tier for your target dose today, compare current tirzepatide program pricing here.